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We demonstrate the use of surface-enhanced Raman spectroscopy
(SERS) as an excellent tool for identifying the binding site of small
molecules on a therapeutically important protein. As an example,
we show the specific binding of the common antihypertension
drug felodipine to the oncogenic Aurora A kinase protein via
hydrogen bonding interactions with Tyr-212 residue to specifically
inhibit its activity. Based on SERS studies, molecular docking,
molecular dynamics simulation, biochemical assays, and point
mutation-based validation, we demonstrate the surface-binding
mode of this molecule in two similar hydrophobic pockets in the
Aurora A kinase. These binding pockets comprise the same unique
hydrophobic patches that may aid in distinguishing human Aurora
A versus human Aurora B kinase in vivo. The application of SERS to
identify the specific interactions between small molecules and
therapeutically important proteins by differentiating competitive
and noncompetitive inhibition demonstrates its ability as a com-
plementary technique. We also present felodipine as a specific
inhibitor for oncogenic Aurora A kinase. Felodipine retards the rate
of tumor progression in a xenografted nude mice model. This study
reveals a potential surface pocket that may be useful for developing
small molecules by selectively targeting the Aurora family kinases.
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Understanding the mechanism of ligand binding to proteins isimperative for designing new molecules or screening po-
tential drug molecules from available databases. We have used
surface-enhanced Raman spectroscopy (SERS), which is a highly
sensitive technique, to understand the binding of the commonly
used hypertension drug, felodipine, to Aurora A kinase. Al-
though NMR (1), X-ray crystallography (2), surface plasmon
resonance (3), and fluorescence (4) are experimental techniques
used to explore protein–drug interactions and each of these
techniques provides unique information about the protein–
ligand interaction, a common problem of these techniques
is the requirement of a high-protein concentration or the in-
corporation of secondary tagged molecules and a protein size
limit. SERS has been traditionally used for the ultrasensitive
detection of analytes. However, it can also be used to examine
the protein–small molecule interactions and elucidate the
mechanism (5–7). A commonly debated aspect is that SERS
does not provide complete vibrational information compared
with resonant Raman or normal Raman spectroscopy. Despite
the limited information from SERS, which can be performed in
proteins at extremely low concentrations in their active state, the
competitive binding versus noncompetitive binding and specific
changes in protein upon ligand binding can be explained. This
approach is extremely effective when combined with molecular
dynamics (MD) simulations and the structural information of
the protein. The usefulness of this combination is that drugs can
be screened for therapeutic applications. This paper provides a
prelude to this development. This finding also facilitates the
developing field of tip-enhanced Raman spectroscopy for im-
aging the small molecule interactions for in vitro and in vivo
applications. A completely developed SERS–MD simulation
combination with adequate help from the structure of the pro-
tein may help converge potential small molecules for therapeutic
applications and reduce the time for drug discovery. A major
advantage of SERS (and Raman spectroscopy) over X-ray
crystallography is that the experiments are carried out with
protein in an active state and does not require special prepara-
tion of the samples.
We present a previously unidentified class of inhibitor-mole-
cule felodipine and demonstrate its selective inhibition of Aurora
A with SERS in a label-free manner and in physiological con-
ditions. The inhibition was achieved using a unique surface-
binding mode and was verified by point-mutation inhibition assays
based on the inputs from SERS andMD simulations. The feasibility
to predicting the binding position of ligands to proteins without
the need for crystallizing the complex and conducting X-ray dif-
fraction studies has demonstrated the potential for a complemen-
tary technique.
Results
Felodipine Inhibits Aurora A Kinase Activity: Tracked by SERS. Felo-
dipine, which is a dihydropyridine compound that was discovered
as a calcium channel antagonist, is an extensively used antihy-
pertensive drug used to treat high blood pressure accompanied
by an increased heart rate (8). A 36% reduction in cancer risk
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was observed in patients administered felodipine (9). Recent
studies have shown that felodipine inhibits cell proliferation in
human smooth muscle cell (10). These observations motivated us
to evaluate the effect of felodipine on cellular proliferation-
related molecular targets.
A previous study from our group had suggested that anacardic
acid is an Aurora A specific activator (11). We attempted to
address the selective inhibition of Aurora A kinase by differen-
tiating it from the closely related Aurora B kinase. The small-
molecule inhibitors that have been shown to target Aurora A
specifically are all ATP analogs that bind within the catalytic
pocket. In this context we were encouraged to screen a dihy-
dropyridine scaffold (such as felodipine, nitrendipine, nimodi-
pine, nicardipine, and amlodipine) against the Aurora family of
mitotic kinases (Fig. S1A). Felodipine and nitrendipine were
shown to inhibit the kinase activity of the recombinant, full-
length, Aurora A in vitro (Fig. S1 B–E). Felodipine can potently
inhibit histone H3 phosphorylation by Aurora A in a dose-
dependent manner but has a minimal effect on the homolog
Aurora B (Fig. 1).
As previously mentioned, SERS is an efficient probe for an-
alyzing small-molecule protein interaction. We used SERS to
understand the binding and specific inhibition of Aurora A by
felodipine. Detailed SERS analysis of Aurora A and B has been
performed and discussed (12). We used the mode assignments
to discuss our observations. In our previous studies and the
SERS studies of Aurora kinases, we demonstrated that silver
nanoparticles do not affect kinase activity and do not signifi-
cantly influence protein structure (12–14). To obtain a suitable
SERS spectrum, it is imperative to achieve the effective binding
of the protein to the nanoparticle surface. We used negatively
charged citrate-capped silver nanoparticles to attach the posi-
tively charged regions of the kinase proteins by electrostatic at-
traction at physiological pH. Fig. 2 shows the SERS of both
Aurora A and B in free and complex form with felodipine. A
significant change in the spectrum of Aurora A complexed with
felodipine compared with the spectrum of Aurora B (Fig. 2) was
observed. The SERS spectra of both Aurora A and B are
dominated by bands from the aromatic amino acids Phe, Tyr,
His, and Trp and the amide bands I, II, and III (12). The amide
bands, which are a complex combination of C = O and N–H
vibrations, provide information about the secondary structure
of a protein. To compare the effects of felodipine with a known
inhibitor, we also performed SERS with reversine, which is an
ATP analog-competitive inhibitor for both Aurora A and B. To
show that protein modes are not influenced by ligand molecules,
the nanoparticle solution, the protein buffer, or even the DMSO
(Sigma) solvent, we individually conducted the SERS and
Raman spectroscopy of these moieties. The results indicated no
interference from these factors over the protein spectra (Fig. S2
A–E). Therefore, the new or shifted modes seen in the SERS
spectrum of Aurora A–felodipine complex are attributed to the
effect of felodipine on the protein.
In quantifying the degree of phosphorylation in the in vitro
kinase assay, the results show that felodipine may inhibit the
kinase activity of Aurora A with an IC50 value of ∼20 μM (Fig.
1C). The kinase activity of Aurora A may be completely inhibited
at a 100-μM concentration of felodipine. In the same assay sys-
tem, felodipine did not affect the kinase activity of Aurora B at
a concentration of 200 μM, which is 10 times higher than the IC50
against Aurora A. These results are consistent with our SERS data.
We have cross-checked our kinase assay by comparing the
inhibitory activity of felodipine with the commercially available
specific inhibitor of Aurora A MLN8237 with an IC50 of 61 nM
(SI Results and Discussion, section 1.1 and Fig. S3) (15). In our
kinase assays both felodipine and MLN8237 can inhibit Aurora
A without affecting the kinase activity of Aurora B. In addition,
felodipine inhibits the autophosphorylation of Aurora A in a
dose-dependent manner (SI Results and Discussion, section 1.2
and Fig. S3) with an IC50 of 20 μM (Fig. S3D) and is also de-
termined to have substrate-specific inhibition of Aurora A in
cellular systems, as indicated by the assays performed in HeLa S3
(SI Results and Discussion, section 1.3 and Fig. S4). The cellular
IC50 for the five cell types in the study (HeLa S3, HEK293T,
MCF7, HCT116, and C6 cells) against Aurora A and B kinases
were in the range of 6 and 12 μM, respectively (Fig. S4G). The
inhibition potential against a panel of 30 mitotic kinases was
tested in the presence of 20 micromolar felodipine as listed in
Table S1.
Prediction of Unique Surface-Binding Mode Using SERS. The most
significant change in the spectrum of the Aurora A–felodipine
complex was the shift of the amide I band from 1,620 to
1,647 cm−1 (Fig. 2A, Inset) which was not observed in the case of
the Aurora B–felodipine complex (Fig. 2B, Inset). We believe
that felodipine is a surface-binding ligand and the change in the
amide I band may have originated from the change in position of
the attachment of the protein on the silver surface (schematically
represented in Fig. 2 C and D). To confirm this hypothesis, we
complexed the protein with another known Aurora A inhibitor–
reversine (a dual-competitive inhibitor), which binds in the ATP
pocket (Fig. 3 A and B) (16). The choice of reversine was in-
tentional because it inhibits both Aurora A and B and the
structural information of binding with Aurora A exists in the
literature (16), thus it could act as a control. Because reversine
is not a surface-binding ligand, attachment of the protein on
a nanoparticle should not be affected and the SERS spectra
should not change. As expected, the SERS spectra (Fig. 3 C and
D) revealed that the amide band shows no shift in its position on
the Aurora A complexed with reversine. In addition, we did not
observe any significant change in the protein SERS spectra for
either kinase. However, two new peaks appeared at around 1,297
and 1,369 cm−1 for the Aurora A–reversine complex and around
1,293 and 1,376 cm−1 for the Aurora B–reversine complex. To
verify whether these originated from the reversine, we performed
normal Raman and SERS on the reversine molecule (Fig. S2 C
and D). The new peaks, shown in Fig. 3 C and D, corresponded
Fig. 1. Felodipine inhibits Aurora A in a dose-dependent manner. (A) Au-
rora A (40 ng) was incubated with recombinant histone H3 and 2.5 μM [γ-32P]
ATP in the presence of an increasing concentration of felodipine (10, 20, 40,
60, 80, and 100 μM). In a similar experiment (B) histone H3 was incubated
with Aurora B (40 ng) and [γ-32P] ATP (lane 1), with DMSO, and with in-
creasing concentration of felodipine (10, 20, 40, 60, 80, 100, 150, and 200 μM)
and subjected to autoradiography. (C) Band intensity was quantified using
a Fuji film PhosphorImager analyzer and plotted as a bar chart representing
the extent of phosphorylation. Error bars represent SDs calculated for three
independent experiments.
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with the strong peaks of the SERS spectra of reversine at high
concentrations (2 mM), whereas reversine failed to yield any
observable peaks at lower concentrations. These observations
suggest that the surface binding of felodipine can be manifested
as a noncompetitive inhibition because these binding pockets
may be far from the catalytic active site.
Validation of SERS Results Through Molecular Docking and MD
Simulations. To validate the experimental evidence of felodi-
pine binding to Aurora A, we performed molecular docking to
predict the binding site and orientation of felodipine. Molecular
docking was assisted by the knowledge of the structure of human
Aurora A (17) and B (18). Docking results showed that felodi-
pine binds to a solvent-exposed pocket outside the hinge region
(Fig. 4 A and B and Fig. S5A) in the most favorable docked pose
(lowest binding energy) and it is in hydrophobic contact with
the residues Phe157, Ile-158, and Tyr-212 (Fig. 4B). Moreover,
the carbonyl group of felodipine forms a hydrogen bond with the −
NH group of the Tyr-212 residue (−O···HN, d = 2.05 Å, Ɵ =
170.45°), which is a part of the solvent-exposed front pocket of
Aurora A located on the flip side of the catalytic pocket in the
hinge region (amino acid residues 210–216). In the case of human
Aurora B, the hydrophobic pocket is narrower by ∼2.8 Å (Fig. S5
B, i and ii and C) compared with the hydrophobic pocket of Aurora
A because the residues Phe-101 and Ile-102 tilt inwards. Thus,
a smaller hydrophobic pocket does not favor felodipine binding
at this surface pocket of human Aurora B and selectively inhibits
human Aurora A. This change in the hydrophobic pocket is at-
tributed to the differences in the nature of the residues that line it
(Lys-156 for Aurora A and His-100 for its counterpart, Aurora B)
in the case of human Aurora kinases (Fig. S5D) but not in the case
of the Xenopus Aurora kinases (Fig. S5E). Because docking was
accomplished with a flexible ligand on a rigid receptor, we also
performed MD simulation to consider the flexibility in protein
structure from the felodipine binding. The 2-ns MD simulation of
the Aurora A–felodipine complex demonstrated the stability of the
binding between felodipine and Aurora A. The rmsd distances
between the center of masses of felodipine and the residues Phe-157,
Ile-158, and Tyr-212 and the protein yielded consistent values over
the entire duration of simulation (Fig S6A).
The comparison of the structures of Aurora A after 2-ns
simulation with and without felodipine revealed a number of
conformational changes that lined the active site, which may
affect the binding of ATP in the ATP-binding pocket (Figs. S5A
and S6B). Residues 141–143 in the glycine-rich loop are highly
flexible and Lys-143 has been shown to be a switch in the case of
ATP binding in Aurora A (19). We also analyzed the second
most favorable docked pose in which the felodipine was hydro-
gen bonded to the residues His-201 and Trp-128. The MD
simulations indicated the stability of felodipine in this hydro-
phobic site (SI Results and Discussion, section 1.4 and Fig. S7 A
and C). We also probed the docking of felodipine to another
hydrophobic site that is similar to the two previous sites with two
aromatic residues coming together (Tyr-334 and Tyr-338). In the
course of the MD simulation, felodipine did not exhibit stable
binding within this pocket (Fig. S7D). As an analogy to the
binding of felodipine with Aurora A selectively, the Aurora B
activator protein, INCENP binds in the vicinity of these surface
pockets (hinge and N-terminal hydrophobic pocket) over Aurora
B but not Aurora A. This finding suggests the uniqueness of one
of the hydrophobic binding sites, which can be targeted for se-
lective inhibition of human Aurora kinases.
Point-Mutation and Kinetics Studies. To physically confirm the
binding of felodipine, we performed point-mutation studies. The
results confirmed our prediction of the binding site because we
obtained a maximum decrease in inhibitory activity of 37% from
the complete inhibition of Aurora A activity for 100 μM felodi-
pine (Fig. 4 C and D). Because the complete rescue was not
observed, a probable second site is suggested as predicted by
docking studies. SERS of Aurora A mutants complexed with
felodipine were performed. In case of the combination mutants
Ile-158 and Tyr-212, as well as Phe-157 and Tyr-212, significant
changes in the SERS spectra were not observed, compared with
the changes seen in the wild-type SERS spectra (Fig. S6C). The
possibility of a second site binding over the enzyme-inhibition
potential of felodipine was validated by performing additional
mutations, namely His-201 and Trp-128. Because Trp-128, when
mutated to Alanine, did not show any kinase activity, we per-
formed our studies using only the His-201 Ala mutant to com-
pare with the wild-type kinase. Based on the in vitro assay (Fig. 4
E and F), no significant difference in the inhibition level of
Fig. 2. SERS study of specific binding of felodipine to Aurora A. (A) SERS
spectrum of Aurora A (black) and Aurora A complexed with felodipine
(red). (B) SERS spectrum of Aurora B (black) and after treatment with
felodipine (red). The change in position of modes and appearance of
new modes are indicated by blue arrows in A and amide I bands are
highlighted in Insets. (C ) Mode of attachment of Aurora A to a silver
nanoparticle and (D) change in orientation of Aurora A on the silver nano-
particle surface on complexation with felodipine. The N-terminal β-sheet–
rich domain and the C-terminal α-helix–rich domains are highlighted in
blue and green, respectively. The bound felodipine in D is highlighted
in red.
Fig. 3. SERS study of competitive inhibition of Aurora A and B by Reversine.
A and B show the structure of Aurora A and B, respectively. The N-terminal
β-sheet–rich domain and the C-terminal α-helix–rich domains are highlighted
in blue and green, respectively. The ATP binding region where reversine
binds is highlighted in red. (C) SERS spectra of Aurora A (black) and Aurora
A–reversine complex (blue). (D) SERS spectra of Aurora B (black) and Aurora
B–reversine complex (red). New modes are indicated by arrows.
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felodipine was observed against both the Aurora A kinases (wild
type versus His-201 Ala) due to the binding of felodipine to the
first site. In the case of point-mutant His-201, large-scale changes
in the SERS spectrum could be observed when complexed with
felodipine. These changes include the shift of the amide I band
from 1,625 to 1645 cm−1, which indicates the shift of the at-
tachment point of the nanoparticle to the α-helix domain (Fig. S6
C, iii). These changes are comparable to the SERS spectra of the
wild type complexed with felodipine. Thus, the most preferable
site of felodipine binding is the hinge pocket surrounded by the
hydrophobic residues Phe-157, Ile-158, and Tyr-212.
The data obtained by SERS, molecular docking, and MD
suggests that felodipine is an uncompetitive inhibitor of Aurora
A. A kinetic characterization of the enzyme inhibition was per-
formed using a fixed concentration of enzyme and histone H3
with an increasing concentration of [γ-32P] ATP in the presence
of varying concentrations of felodipine using DMSO as solvent
control. The results are presented in SI Results and Discussion,
section 1.5 and Fig. S8. It was observed that, unlike the majority
of the ATP-competitive inhibitors reported for Aurora kinase,
felodipine is a mixed-type inhibitor of Aurora A. These obser-
vations indicate that SERS-based prediction of a noncom-
petitive mode of inhibition is valid.
Cell Cycle and In Vivo Effects of Felodipine: Spindle Pole Defects, Cell
Death, and Retardation of Tumor Progression. The effects of felo-
dipine on the cell cycle were investigated by FACS analysis using
four different cell lines: HeLa, HEK293T, MCF7, and HCT116
cells (Fig. S9). The results showed that felodipine can induce a dose-
dependent increase in aneuploidy compared with DMSO control
(SI Results and Discussion, section 1.6 and Fig. S10 B–E).
Aurora A inhibition induces aneuploidy, which causes cell
death (20). We determined that the use of felodipine for the
inhibition of Aurora A also induces cell death in HeLa cells, as
revealed from the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy-
methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay.
Considering untreated cells as a 100% viable population, the
viability of cells treated with an increasing concentration of
felodipine was compared with the DMSO treatment. Nearly 87%
of cell death was observed in the case of 100 μM felodipine-
treated cells (Fig. S10A). This finding suggests that felodipine
induces cell death in high micromolar concentrations. Mecha-
nistically, the inhibition of Aurora A by felodipine may induce
spindle pole defects that cause chromosome congressional
problems at metaphase, which results in aneuploidy, as observed
in Aurora A knockdown cells (20). Our investigations of the
spindle pole morphology in HeLa cells, after felodipine treat-
ment by immunocytochemistry analysis using the anti–α-tubulin
antibody, unambiguously established the onset of spindle defects.
Among all cell lines tested for the felodipine-mediated in-
duction of aneuploidy, the most robust effect was observed in the
case of the rapidly proliferating C6 glioma cells. Thus, the C6 cell
lines were selected to investigate the effect of felodipine in a
xenografted nude mice model. We injected 106 cells in the s.c.
tissue of the left flank in mice. After 1 wk, these mice were
challenged with only DMSO or with felodipine at the rate of
5 mg/kg body weight daily for 4 wk. At the end of every week the
tumor size was measured and plotted as the percent tumor pro-
gression for mice treated with DMSO and felodipine (n = 3) versus
days posttreatment in weeks. We obtained a significant reduction in
the tumor progression rate among the mice treated with felodipine
compared with mice injected with DMSO (Fig. S10F).
Discussion
In the majority of drug-designing strategies, the small-molecule
modulator with the greatest potency is selected. However, the
modulator’s target specificity is compromised. Similarly, small
molecules, which are highly specific, may not be investigated to
their full potential due to a high IC50. This scenario becomes
more difficult with surface-binding molecules. Based on our
results, we located the binding site of one of the surface-binding
small-molecule modulators (felodipine), selectively inhibiting
Aurora A using SERS, to our knowledge for the first time, and
corroborated using molecular docking studies and MD simu-
lations. Due to the simplicity of these studies, the potential to
screen drugs and derivatize these small molecules with high IC50
to develop new drugs with better potency exists. Various other
advantages and disadvantages of SERS are highlighted in SI
Results and Discussion, section 1.7.
SERS to Explain the Noncompetitive Surface-Binding Mode. SERS
was used to show the direct evidence of the unique surface-
binding mode for felodipine. The changes observed in the in-
tensity of SERS modes are attributed to the change in
the binding nature of the protein to the nanoparticle surface.
Structurally Aurora A is bilobed with a N-terminal lobe that
primarily consists of β-sheets and a C-terminal lobe, which pre-
dominantly consist of α-helices. The 1,620-cm−1 peak is a char-
acteristic peak of the antiparallel β-sheet, which suggests that the
N-terminal lobe of the protein is bound to the silver nanoparticle
surface. The change in spectra (where the amide I band shifts
from 1,620 to 1,647 cm−1) when complexed with felodipine is
significant because it suggests that the protein-binding region has
been altered due to the presence of felodipine. Note that felo-
dipine possesses a strong hydrophobic region (chloride region)
and a hydrophilic region (pyridine region). We did not observe
any felodipine signature in the spectra. This result suggests that
the hydrophobic region of felodipine faces outwards, repelling
the silver because it would prefer to be in a hydrophilic region.
This finding also suggests that felodipine is bound to the surface
of the protein. Based on the amide I mode obtained from the
Fig. 4. Noncompetitive binding of felodipine to Aurora A. (A) Conforma-
tional clustering histogram generated frommolecular docking of felodipine to
Aurora A through Autodock. Red arrows represent the conformations of
felodipine bound to the hinge pocket (first site), whereas black arrows rep-
resent binding over the N-terminal pocket (second site). (B) The bound con-
figuration of felodipine to Aurora A. The residues colored in gray are in
hydrophobic interaction with felodipine. Felodipine is hydrogen bonded to
Aurora A through residue Tyr-212 (dotted line). The carbon, oxygen, nitrogen,
and chlorine atoms are colored in yellow, red, blue, and green, respectively.
Inset shows the felodipine (blue) attached to the surface of Aurora A near the
hinge region. (C) Aurora A kinase assay with DMSO control and with an in-
creasing concentration of felodipine using wild type versus mutant kinases
(amount normalized with wild-type activity) and subjected to autoradiogra-
phy. I and II represent autoradiogram and coomassie, respectively. (D) The
band intensity was quantified and plotted as a bar chart representing the
extent of phosphorylation. Error bars represent SDs calculated for three in-
dependent experiments. (E) In vitro kinase assay that compares the wild-type
versus second-site mutant (H201A), which is similar to C. (F) The quantification
for the same data are represented as a bar chart, which is similar to D.
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felodipine-complexed protein, the enzyme is predominantly
attached to the nanoparticle’s surface through the α-helix
(characteristic amide I bands vary from 1,640 to 1,658 cm−1),
which exists in the C-terminal lobe. Based on these observations,
two possible events may occur in tandem. The binding of felo-
dipine to the hinge pocket and the second site, which is located
in the β-sheet–rich N terminus followed by the blocking of the
N-terminal lobe from contacting the nanoparticle surface. Thus,
the protein is left with the option of binding the nanoparticle
through the α-helical domain. This result is corroborated by
large-scale changes in the intensities of modes from aromatic
amino acids and other aliphatic side chain modes.
The felodipine binding changes the shape of the ATP-binding
hydrophobic pocket; more prominently in the glycine-rich loop
(Figs. S5A and S6B). This occurrence is confirmed from the
SERS of the Aurora B and Aurora B–felodipine complex. Be-
cause we do not find any change in the amide I region, it suggests
that felodipine is not binding at the hinge region. Note that
Aurora B exhibits a similar structure to Aurora A (21). Because
reversine binds to both Aurora A and B competitively from
within the ATP-binding pocket (16), it cannot alter the envi-
ronment around the N-terminal lobe of the protein. The SERS
of both Aurora A and B complexed with reversine does not show
a change in the amide I mode but shows the appearance of the
strong reversine modes around 1,297 and 1,372 cm−1. In addition
there was very little change in the intensities of modes of aro-
matic amino acids in the case of reversine binding to Aurora
kinases. The fact that one can see the SERS of reversine (which
requires a high concentration to be visible in the absence of
protein), suggests that the protein becomes adsorbed onto the
silver nanoparticle close to the hinge region toward the N-ter-
minal lobe. Thus, SERS can clearly differentiate different modes
of binding for two different molecules and give a hand-waving
argument for the different inhibitory mechanisms.
Mechanistic Insights Using Molecular Docking and MD. Docking and
MD studies validated the existence of a unique surface-binding
mode in the vicinity of the β-sheet domain, as observed by SERS.
The binding of felodipine was ranked according to the binding
energies by Autodock (22). The results indicated two potential
sites of interaction (Fig. 4A). Felodipine presumably binds near
the solvent-exposed hydrophobic pocket outside the hinge region
in Aurora A formed by residues Phe-157, Ile-158, and Tyr-212,
which has a minimum binding energy and maximum population
(first site). These residues create a partly hydrophobic cavity to
accommodate the hydrophobic backbone of felodipine, which is
lined by a hydrophilic cavity to accommodate the hydrophilic
side chains. The change in dimensions of this pocket results in
the reduction of the hydrophobic patch in this region by ap-
proximately 2.8 Å (Fig. S5C) in the human Aurora kinase, which
prevents felodipine from binding to Aurora B and makes it a
selective inhibitor for human Aurora A. Binding of a ligand to
specific sites on a protein is highly dependent on complemen-
tarity in terms of the protein–ligand geometry and electrostatic
forces between protein and ligand. Therefore, the detection of
binding sites or cavities on proteins has important implications in
the area of structural biology. Felodipine exhibits uncompetitive
inhibition and reduces the autophosphorylation in Aurora A,
which indicates a specific level of conformation changes within
the active sites of the protein. These allosteric inhibitors, which bind
outside the active site of the protein, cause global conformational
change and regulate the kinase activity of the protein target. MD
considers the flexibility of the protein and shows a distinct confor-
mational change in the residues lining the active site of the protein.
Residues 141–143 are flexible and have high rmsd values, as shown
in Fig. S6B. The residue Lys-143 has been shown to be crucial for
the binding and release of ATP in the binding site. The state of Lys-
143 is controlled by the hydrogen-bonded network between TPX2,
which activates Aurora A and the β-sheet region connected to the
glycine-rich loop that undergoes translational movement. Because
felodipine engages in a hydrophobic interaction with the residues
Phe-157 and Ile-158, both of which are part of the β-sheet region,
the movement of the glycine-rich loop is expected to occur in the
same manner. The global alteration in the conformation is also
communicated to the α-helix loop (Fig. S5A), which is responsible
for maintaining the phosphorylated Thr-288 in its active confor-
mation. Isothermal titration calorimetry (ITC) experiments suggest
the existence of two binding sites. The second site was also pre-
dicted by Autodock. This site is located on the N-terminal domain
of Aurora A, which is lined by the residues Trp-128 and His-201.
Although the MD simulation exhibits the stable binding of felodi-
pine, biochemical assays that use the point mutants did not show
any perturbation at the level of the kinase activity for the tested
mutant. The lack of activity in the Trp-128 mutant did not allow us
to biochemically corroborate the binding convincingly over this
pocket. MD simulations also show a slight perturbation of the ATP-
binding pocket (residues 210–215; Fig. S6D) after complexing with
felodipine at the second site. This situation may be the reason that
rescue is not completely achieved with the first site mutants.
Role of Felodipine. Because felodipine shows inhibition of Aurora
A autophosphorylation and substrates, such as TACC3 and
H3S10, it may confer cytotoxicity. Thus, additional derivitization
based on the information obtained from this study can lead
to the development of specific Aurora A inhibitors, which may
serve as future antitumor therapeutics.
The majority of the known small molecules that inhibit Aurora
kinase are competitive inhibitors that bind to the ATP-binding
pocket of the enzymes (23). However, few inhibitors that selec-
tively inhibit Aurora A, such as MLN8054 (24) and MLN8237
(25), exist. MLN8054 possess a benzazepine core scaffold with
a fused amino pyrimidine ring and an aryl carboxylic acid that
shows ATP-competitive and reversible inhibition of recombinant
Aurora A with an IC50 of 42 nM; it had failed in phase I clinical
trials on advanced solid tumors (24). Similarly MLN8237 is also
a selective and potent competitive inhibitor of Aurora A, which
has a pyrimidine-fused benzazepine scaffold with an IC50 of 61
nM. Felodipine, on the other hand, is an uncompetitive inhibitor
of Aurora A with low micromolar IC50. MLN8054 treatment
induces G2/M arrest due to spindle defect, and prolonged
treatment induces aneuploidy, which ultimately leads to apo-
ptosis. A similar effect may also be observed after felodipine
treatment, which indicates that felodipine inhibits Aurora A in
the cellular system. MLN8054 induces 82% spindle abnormality
(26), whereas felodipine can induce a maximum spindle abnor-
mality of 40%. Felodipine was found to be cytotoxic, which may
be attributed to its dihydropyridine scaffold. This assumption is
supported by the fact that the dihyropyridine group of com-
pounds can reverse drug resistance in multidrug-resistant cancer
cells (27, 28). Further, this class of drugs may block the dihy-
dropyridine receptor (DHPR) thereby reducing the cytosolic Ca2+
levels essential for activating the calcium dependant signaling
events. Recently, Ca2+ was shown to activate Aurora A auto-
phosphorylation in a calmodulin (CaM)-dependant manner (24,
29). Our current observations and previous studies (30) suggest
that felodipine, can also inhibit calcium-mediated activation be-
cause dihydropyridine can block the cytosolic Ca2+ release by
blocking the DHPR, which is an indirect means by which Au-
rora A activity is inhibited within the cell. Furthermore, many
other CaM-dependent pathways may be blocked within the cell.
Collectively, these data suggest that felodipine induces aneu-
ploidy by inhibiting Aurora A and causing G2/M arrest. The
majority of these effects comprise only a part of the function
served by felodipine, with many unidentified targets, which
requires careful investigation to design more potent and selective
inhibitors of Aurora A. In addition, our observations indicated
a reduction in the tumor progression rate among the mice
treated with felodipine. Although felodipine cannot be adminis-
tered to achieve micromolar concentrations in vivo, the multiple
modes of action, such as calcium channel blockade and CaM
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pathway blocking, and additionally, the direct inhibition of Aurora
A kinase, prove effective in the total retardation of tumor growth.
Conclusion
We have demonstrated that SERS can be performed at relatively
low concentration and provide vital insight into the binding of small
molecules to the protein. With the structural information of the
protein, molecular docking, and MD studies, we can corroborate
these results and highlight the binding site of the small molecule on
the protein. This finding has been demonstrated in the case of
Aurora kinases and felodipine. SERS can distinguish between sur-
face binding and competitive binding of small molecules of Aurora
A kinase. Point mutations performed on the Aurora kinase confirm
the binding mechanism predicted by these techniques. Thus, SERS,
molecular docking, and MD can be combined to provide an
alternative to the current methods used for drug discovery.
A properly developed SERS methodology for individual proteins
can be used for rapid screening of possible ligands for thera-
peutic applications. At this juncture, we are enthusiastic to think
that, as with valproic acid (31), felodipine-related compounds
may soon also be considered as antineoplastic therapeutics.
Materials and Methods
Purification of Enzymes and Substrates and Kinase Assay. Aurora A and B
enzymes expressed as C-terminal His6-tagged proteins were purified using
Ni·nitrilotriacetic acid affinity purification from the respective, recombinant
baculovirus infected Sf21 cells. Details of the procedure, kinetic assay, and ITC
experiments are described in SI Materials and Methods, sections 2.1–2.3.
Cell Culture, Treatment, Immunoblotting Analysis, and FACS Analysis. The
preparation of mammalian cells and the methods for immunoblotting,
cell cycle analysis, and FACS are described in SI Materials and Methods,
section 2.4.
MTS Assay and Immunofluorescence. Details on the MTS and immunofluo-
rescence assays performed on cultures of HeLa cells treated with DMSO/
felodipine are explained in SI Materials and Methods, section 2.5.
Ethics Statement and Animal Experiment. All animal experiments were per-
formed as per committee for the purpose of control and supervision of
experiments on animals (CPSEA) guidelines with the approval of animal facility,
Jawaharlal Nehru Centre for Advanced Scientific Research. Nudemice procured
from the National Institute of Virology (Pune, India) were used for tumor
growth rate studies. For details, see SI Materials and Methods, section 2.6.
Raman and SERS. All Raman and SERS measurements were performed using
a custom-built Raman spectrometer. The instrumentation and sample
preparation methods are discussed in SI Materials and Methods, section 2.7.
MD Simulations. The initial structures of human Aurora A and B were
obtained from the Protein Data Bank [ID codes 1MQ4 (32) and 4AF3 (18)]. The
structures of ligands were optimized by the Gaussian 09 program (33). The
MD simulation of human Aurora A was performed by the MD package
nanoscale molecular dynamics (NAMD, Version 2.8; www.ks.uiuc.edu/
Research/namd) using the chemistry at Harvard molecular mechanics 22
(CHARMM22) (34) force field. Details of the methods are discussed in SI
Materials and Methods, section 2.8.
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